The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Pharmaceutical CRDMO Service Market Research Report 2024
Synopsis
Global Pharmaceutical CRDMO Service market is projected to reach US$ 130.6 million in 2029, increasing from US$ 83 million in 2022, with the CAGR of 6.8% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Pharmaceutical CRDMO Service market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Pharmaceutical CRDMO Service market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
BioDuro-Sundia
Sai Life Sciences
Icosagen
WuXi Biologics
WuXi AppTec
Esco Aster
Jubilant Biosys
Syngene International
Chemveda
Ardena Holding
Eurofins
Jiangsu HUAYI Technology Co., Ltd.
Segment by Type
Small Molecule CRDMO Service
Middle Molecule CRDMO Service
Large Molecule CRDMO Service
Segment by Application
Oncology
Infectious Disease
Neurology
Immunology
Hematology
Vaccine
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Pharmaceutical CRDMO Service report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Global Pharmaceutical CRDMO Service market is projected to reach US$ 130.6 million in 2029, increasing from US$ 83 million in 2022, with the CAGR of 6.8% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Pharmaceutical CRDMO Service market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Pharmaceutical CRDMO Service market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
BioDuro-Sundia
Sai Life Sciences
Icosagen
WuXi Biologics
WuXi AppTec
Esco Aster
Jubilant Biosys
Syngene International
Chemveda
Ardena Holding
Eurofins
Jiangsu HUAYI Technology Co., Ltd.
Segment by Type
Small Molecule CRDMO Service
Middle Molecule CRDMO Service
Large Molecule CRDMO Service
Segment by Application
Oncology
Infectious Disease
Neurology
Immunology
Hematology
Vaccine
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Pharmaceutical CRDMO Service report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Pharmaceutical CRDMO Service Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Small Molecule CRDMO Service
1.2.3 Middle Molecule CRDMO Service
1.2.4 Large Molecule CRDMO Service
1.3 Market by Application
1.3.1 Global Pharmaceutical CRDMO Service Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Oncology
1.3.3 Infectious Disease
1.3.4 Neurology
1.3.5 Immunology
1.3.6 Hematology
1.3.7 Vaccine
1.3.8 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Pharmaceutical CRDMO Service Market Perspective (2018-2029)
2.2 Pharmaceutical CRDMO Service Growth Trends by Region
2.2.1 Global Pharmaceutical CRDMO Service Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Pharmaceutical CRDMO Service Historic Market Size by Region (2018-2023)
2.2.3 Pharmaceutical CRDMO Service Forecasted Market Size by Region (2024-2029)
2.3 Pharmaceutical CRDMO Service Market Dynamics
2.3.1 Pharmaceutical CRDMO Service Industry Trends
2.3.2 Pharmaceutical CRDMO Service Market Drivers
2.3.3 Pharmaceutical CRDMO Service Market Challenges
2.3.4 Pharmaceutical CRDMO Service Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Pharmaceutical CRDMO Service Players by Revenue
3.1.1 Global Top Pharmaceutical CRDMO Service Players by Revenue (2018-2023)
3.1.2 Global Pharmaceutical CRDMO Service Revenue Market Share by Players (2018-2023)
3.2 Global Pharmaceutical CRDMO Service Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Pharmaceutical CRDMO Service Revenue
3.4 Global Pharmaceutical CRDMO Service Market Concentration Ratio
3.4.1 Global Pharmaceutical CRDMO Service Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Pharmaceutical CRDMO Service Revenue in 2022
3.5 Pharmaceutical CRDMO Service Key Players Head office and Area Served
3.6 Key Players Pharmaceutical CRDMO Service Product Solution and Service
3.7 Date of Enter into Pharmaceutical CRDMO Service Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Pharmaceutical CRDMO Service Breakdown Data by Type
4.1 Global Pharmaceutical CRDMO Service Historic Market Size by Type (2018-2023)
4.2 Global Pharmaceutical CRDMO Service Forecasted Market Size by Type (2024-2029)
5 Pharmaceutical CRDMO Service Breakdown Data by Application
5.1 Global Pharmaceutical CRDMO Service Historic Market Size by Application (2018-2023)
5.2 Global Pharmaceutical CRDMO Service Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Pharmaceutical CRDMO Service Market Size (2018-2029)
6.2 North America Pharmaceutical CRDMO Service Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Pharmaceutical CRDMO Service Market Size by Country (2018-2023)
6.4 North America Pharmaceutical CRDMO Service Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Pharmaceutical CRDMO Service Market Size (2018-2029)
7.2 Europe Pharmaceutical CRDMO Service Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Pharmaceutical CRDMO Service Market Size by Country (2018-2023)
7.4 Europe Pharmaceutical CRDMO Service Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Pharmaceutical CRDMO Service Market Size (2018-2029)
8.2 Asia-Pacific Pharmaceutical CRDMO Service Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Pharmaceutical CRDMO Service Market Size by Region (2018-2023)
8.4 Asia-Pacific Pharmaceutical CRDMO Service Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Pharmaceutical CRDMO Service Market Size (2018-2029)
9.2 Latin America Pharmaceutical CRDMO Service Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Pharmaceutical CRDMO Service Market Size by Country (2018-2023)
9.4 Latin America Pharmaceutical CRDMO Service Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Pharmaceutical CRDMO Service Market Size (2018-2029)
10.2 Middle East & Africa Pharmaceutical CRDMO Service Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Pharmaceutical CRDMO Service Market Size by Country (2018-2023)
10.4 Middle East & Africa Pharmaceutical CRDMO Service Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 BioDuro-Sundia
11.1.1 BioDuro-Sundia Company Detail
11.1.2 BioDuro-Sundia Business Overview
11.1.3 BioDuro-Sundia Pharmaceutical CRDMO Service Introduction
11.1.4 BioDuro-Sundia Revenue in Pharmaceutical CRDMO Service Business (2018-2023)
11.1.5 BioDuro-Sundia Recent Development
11.2 Sai Life Sciences
11.2.1 Sai Life Sciences Company Detail
11.2.2 Sai Life Sciences Business Overview
11.2.3 Sai Life Sciences Pharmaceutical CRDMO Service Introduction
11.2.4 Sai Life Sciences Revenue in Pharmaceutical CRDMO Service Business (2018-2023)
11.2.5 Sai Life Sciences Recent Development
11.3 Icosagen
11.3.1 Icosagen Company Detail
11.3.2 Icosagen Business Overview
11.3.3 Icosagen Pharmaceutical CRDMO Service Introduction
11.3.4 Icosagen Revenue in Pharmaceutical CRDMO Service Business (2018-2023)
11.3.5 Icosagen Recent Development
11.4 WuXi Biologics
11.4.1 WuXi Biologics Company Detail
11.4.2 WuXi Biologics Business Overview
11.4.3 WuXi Biologics Pharmaceutical CRDMO Service Introduction
11.4.4 WuXi Biologics Revenue in Pharmaceutical CRDMO Service Business (2018-2023)
11.4.5 WuXi Biologics Recent Development
11.5 WuXi AppTec
11.5.1 WuXi AppTec Company Detail
11.5.2 WuXi AppTec Business Overview
11.5.3 WuXi AppTec Pharmaceutical CRDMO Service Introduction
11.5.4 WuXi AppTec Revenue in Pharmaceutical CRDMO Service Business (2018-2023)
11.5.5 WuXi AppTec Recent Development
11.6 Esco Aster
11.6.1 Esco Aster Company Detail
11.6.2 Esco Aster Business Overview
11.6.3 Esco Aster Pharmaceutical CRDMO Service Introduction
11.6.4 Esco Aster Revenue in Pharmaceutical CRDMO Service Business (2018-2023)
11.6.5 Esco Aster Recent Development
11.7 Jubilant Biosys
11.7.1 Jubilant Biosys Company Detail
11.7.2 Jubilant Biosys Business Overview
11.7.3 Jubilant Biosys Pharmaceutical CRDMO Service Introduction
11.7.4 Jubilant Biosys Revenue in Pharmaceutical CRDMO Service Business (2018-2023)
11.7.5 Jubilant Biosys Recent Development
11.8 Syngene International
11.8.1 Syngene International Company Detail
11.8.2 Syngene International Business Overview
11.8.3 Syngene International Pharmaceutical CRDMO Service Introduction
11.8.4 Syngene International Revenue in Pharmaceutical CRDMO Service Business (2018-2023)
11.8.5 Syngene International Recent Development
11.9 Chemveda
11.9.1 Chemveda Company Detail
11.9.2 Chemveda Business Overview
11.9.3 Chemveda Pharmaceutical CRDMO Service Introduction
11.9.4 Chemveda Revenue in Pharmaceutical CRDMO Service Business (2018-2023)
11.9.5 Chemveda Recent Development
11.10 Ardena Holding
11.10.1 Ardena Holding Company Detail
11.10.2 Ardena Holding Business Overview
11.10.3 Ardena Holding Pharmaceutical CRDMO Service Introduction
11.10.4 Ardena Holding Revenue in Pharmaceutical CRDMO Service Business (2018-2023)
11.10.5 Ardena Holding Recent Development
11.11 Eurofins
11.11.1 Eurofins Company Detail
11.11.2 Eurofins Business Overview
11.11.3 Eurofins Pharmaceutical CRDMO Service Introduction
11.11.4 Eurofins Revenue in Pharmaceutical CRDMO Service Business (2018-2023)
11.11.5 Eurofins Recent Development
11.12 Jiangsu HUAYI Technology Co., Ltd.
11.12.1 Jiangsu HUAYI Technology Co., Ltd. Company Detail
11.12.2 Jiangsu HUAYI Technology Co., Ltd. Business Overview
11.12.3 Jiangsu HUAYI Technology Co., Ltd. Pharmaceutical CRDMO Service Introduction
11.12.4 Jiangsu HUAYI Technology Co., Ltd. Revenue in Pharmaceutical CRDMO Service Business (2018-2023)
11.12.5 Jiangsu HUAYI Technology Co., Ltd. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest IT & Electronics Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
